Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,068.75 Consensus Target Price from Brokerages
Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target […]
More Stories
How to Verify the Security Compliance of Your Third-Party Billing Vendors
When you outsource your billing to a third party, it may give the impression that the associated risk is also...
10+ Best SaaS Marketing Agencies That You Need in 2026
Most B2B SaaS companies still hire partners the same way they did years ago and wonder why their growth graphs...
Top 10 Six Sigma Tools That Will Grow Your Business in 2026
Every company faces the same problems while running its business: repeated mistakes, hidden waste, and insufficient processes that don’t deliver...
Ukraine Reports Crash of One of Its F-16s, Pilot Safe
By Victoria Friedman The Armed Forces of Ukraine said one of its F-16 fighter jets had crashed, and that the...
US Gas Prices Remain Elevated Amid Ongoing Middle East Tensions US Gas Prices Remain Elevated Amid Ongoing Middle East Tensions
By Naveen Athrappully Gasoline prices in the United States continue to remain high at over $4 per gallon as the...
Spain’s Ceuta Overwhelmed as Nearly 60,000 Illegal Immigrants Cross From Morocco in a Day
By Owen Evans Ceuta was overwhelmed overnight as the Spanish North African exclave faced a fresh wave of nearly 60,000...